Nanalysis Arranges $8-Million Public offering

Updated: Jan 21



Nanalysis Scientific Corp. has filed a preliminary short-form prospectus with the securities commissions or similar regulatory authorities in each of the provinces of Canada, except for the province of Quebec, in connection with a best efforts marketed public offering of common shares of the company at an offering price of $1.10 per common share for gross proceeds of up to approximately $8-million.


The offering will be conducted by Echelon Wealth Partners Inc. as lead agent and sole book runner, and is subject to customary closing conditions, including the approval of the securities regulatory authorities and the TSX Venture Exchange.


The offering is expected to close on or about Feb. 15, 2022, or such other date as the company and Echelon may agree.


The company has granted Echelon an option to purchase up to an additional 15 per cent of the common shares sold under the offering at the issue price. The overallotment option may be exercised in whole or in part to as determined by Echelon upon written notice to the company at any time up to 30 days following the closing date of the offering.

The company intends to use the net proceeds of the offering for sales and marketing, strategic acquisitions, and general and working capital purposes.


About Nanalysis Scientific Corp.


Nanalysis trades on the TSX Venture Exchange in with ticker symbol NSCI, Over the Counter under the ticker symbol NSCIF and on the Frankfurt Exchange under the symbol 1N1. Nanalysis is an international business focused on capitalizing its proprietary technologies in magnetic resonance (MR) that go into NMR spectrometers and magnetic resonance imaging (MRI). Nanalysis operates out of two subsidiaries, Nanalysis Corp. and RS2D SAS. Nanalysis Corp. is an industry leader in developing and manufacturing compact MR spectrometers for laboratory and industrial markets. Its advanced 60- and 100-megahertz spectrometers require no liquid helium or other cryogens. These devices are used by chemical professionals spanning a wide variety of industries, including oil and gas, chemical, mining, pharmaceutical, and biotechnology. Through its European subsidiary RS2D, the company's electronic boards and software are used in conventional NMR and MRI equipment, and are being incorporated into next-gen MRI systems as well as miniaturized MRI devices.